Vir Biotechnology issues license to Norgine to market hepatitis D candidate

vir-biotechnology-issues-license-to-norgine-to-market-hepatitis-d-candidate
Hepatitis Concept

eenevski/iStock via Getty Images

  • Vir Biotechnology (VIR) has granted Norgine Pharma UK an exclusive license to market its experimental chronic hepatitis d treatment, a combination of tobevibart and elebsiran, in Europe, Australia, and New Zealand.
  • Tobevibart is a monoclonal antibody, while elebsiran is a small